Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT),Alzheimer's & Dementia

当前位置： X-MOL 学术 › Alzheimers Dement. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT)
Alzheimer's & Dementia ( IF 13.0 ) Pub Date : 2021-11-17 , DOI: 10.1002/alz.12496
Nicholas M Pajewski ₁ , Fanny M Elahi ₂ , Manjula Kurella Tamura ₃ , Jason D Hinman ₄ , Ilya M Nasrallah ₅ , Joachim H Ix ₆ , Lindsay M Miller ₆ , Lenore J Launer ₇ , Clinton B Wright ₈ , Mark A Supiano ₉ , Alan J Lerner ₁₀ , Tiffany L Sudduth ₁₁ , Anthony A Killeen ₁₂ , Alfred K Cheung ₁₃ , David M Reboussin ₁ , Donna M Wilcock ₁₁ , Jeff D Williamson ₁₄

Affiliation

Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Geriatric Research, Education and Clinical Center, Palo Alto Veterans Affairs Health Care System, California and Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA.
Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Division of Nephrology-Hypertension, University of California San Diego, San Diego, California, USA.
Intramural Research Program, National Institute on Aging, Baltimore, Maryland, USA.
National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA.
Geriatric Research, Education and Clinical Center, Veterans Affairs Salt Lake City Health System, Utah and Division of Geriatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Department of Neurology, University Hospitals-Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Department of Physiology, Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.
Renal Section, Veterans Affairs Salt Lake City Healthcare System, Utah and Division of Nephrology and Hypertension, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

Lowering blood pressure (BP) reduces the risk for cognitive impairment and the progression of cerebral white matter lesions. It is unclear whether hypertension control also influences plasma biomarkers related to Alzheimer's disease and non-disease-specific neurodegeneration.

中文翻译：